Intellia Therape (NTLA)

$8.07 0.00 (0.00%)

20:00 EDT NTLA Stock Quote Delayed 30 Minutes

3 Gene Editing Stocks With Unprecedented Surge Potential

By Ian Cooper, InvestorPlace Contributor Feb 13, 2024

While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential.

The 3 Most Undervalued Biotech Stocks to Buy in February 2024

3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential

3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024

Volume:

Previous Close $8.40

Market Cap 869.55M

PE Ratio -1.54

EPS -5.2519

Volume (Avg. Vol.) 2.76M

Day's Range $8.03 - $8.43

52-Week Range $8.03 - $28.18

Dividend & Yield N/A (N/A)

NTLA Stock Predictions, Articles, and Intellia Therape News

Intellia Therapeutics Layoffs 2024: What to Know About the Latest NTLA Job Cuts

By William White, InvestorPlace Writer Jan 5, 2024

Intellia Therapeutics layoffs are in the news on Friday as the biotech company prepares to cut its total workforce by 15% to reduce costs.

3 Gene-Editing Stocks With the Potential to Mint Millionaires

By Alex Sirois, InvestorPlace Contributor Dec 13, 2023

Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR.

3 Biotech Stocks That Are Betting on the Future of Gene Editing

By Chris Markoch, InvestorPlace Contributor Nov 9, 2023

These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.

The 3 Most Promising Biotech Stocks to Own Now

By Michael Que, InvestorPlace Contributor Aug 31, 2023

These top biotech stock picks with high and leading growth potential are must-owns for investors looking for high upside potential.

The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023

By Marie Brodbeck, InvestorPlace Contributor Jul 24, 2023

These three undervalued biotech stocks could have plenty of room to run if their efforts to push out promising pipeline drugs are successful.

The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023

By Gabriel Osorio-Mazzilli, InvestorPlace Contributor Jul 20, 2023

These are the three bargain biotech stocks showcasing massive upside potential for investors looking to find a position in the sector.

Why Is Intellia (NTLA) Stock Up 5% Today?

By Larry Ramer, InvestorPlace Contributor Jun 12, 2023

NTLA stock is trending on social media and is up over 5%. The drugmaker reported new, positive results from its gene-edited treatment.

The 3 Most Promising Gene Editing Stocks to Buy in 2023

By John Blankenhorn, InvestorPlace Contributor Apr 28, 2023

Intellia, Beam, and Editas are using gene editing to cure incurable diseases. These are three gene editing stocks you'll want to invest in.

3 Biotech Stocks to Watch After Johnson & Johnson’s Earnings Beat

By Faizan Farooque, InvestorPlace Contributor Apr 25, 2023

Discover the latest picks in the biotech industry with our article on 3 biotech stocks to watch after Johnson & Johnson’s earnings beat.

3 High-Growth Biotech Stocks Poised for Success in 2023

By Chris Markoch, InvestorPlace Contributor Apr 18, 2023

If you look for growth opportunities wherever you can find them, there are some high-growth biotech stocks that could present an opportunity

Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?

By Josh Enomoto, InvestorPlace Contributor Apr 13, 2023

While CRSPR stock captured the spotlight for potentially encouraging drug data, the news lifted other gene-editing stocks.

7 Biotech Stocks to Buy for Breakthrough Treatments and Cures

By Josh Enomoto, InvestorPlace Contributor Mar 29, 2023

For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine.

The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket

By Ian Cooper, InvestorPlace Contributor Mar 25, 2023

Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it.

7 Cathie Wood Stocks for Your March Buy List

By Alex Sirois, InvestorPlace Contributor Mar 7, 2023

Cathie Wood stocks have staged a turnaround in early 2023 as markets rebound after a miserable 2022.

Why Is Intellia Therapeutics (NTLA) Stock Up 10% Today?

By Josh Enomoto, InvestorPlace Contributor Mar 2, 2023

With the FDA green lighting Intellia’s gene-editing test, NTLA stock jumped on the implications, though some concerns linger.

7 CRISPR Stocks With the Best Long-Term Potential

By Alex Sirois, InvestorPlace Contributor Jan 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later

By Chris Markoch, InvestorPlace Contributor Jan 25, 2023

Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time.

3 Gene Editing Stocks With the Best Long-Term Potential

By Muslim Farooque, InvestorPlace Contributor Jan 25, 2023

These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space

7 ‘Next Big Things’ for Investors to Buy for 2023

By Chris Lau, InvestorPlace Contributor Dec 13, 2022

The next big thing for investors in 2023 is buying companies with revenue expansion amid what could be a painful economic slowdown.

NTLA Stock Falls as Intellia Therapeutics Announces Public Offering

By William White, InvestorPlace Writer Dec 1, 2022

Intellia Therapeutics (NTLA) stock is falling hard on Thursday after the company announced a public stock offering of 6.6 million shares.

Intellia Therape (NTLA)

3 Gene Editing Stocks With Unprecedented Surge Potential

The 3 Most Undervalued Biotech Stocks to Buy in February 2024

3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential

3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Intellia Therape (NTLA)

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

NTLA Stock Predictions, Articles, and Intellia Therape News

Subscriber Sign in